Trial reportJAMA neurology2014
A prospective study of chronic obstructive pulmonary disease and the risk for mild cognitive impairment.
Trial report in JAMA neurology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04394299 (Cognitive Impairment and Clinical Characteristics in Patients With Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cognitive Impairment and Clinical Characteristics in Patients With Chronic Obstructive Pulmonary Disease: Retrospective Study
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Chronic obstructive pulmonary disease as a risk factor for cognitive impairment: a systematic review and meta-analysis.BMJ open respiratory research · 2024Pooled it
- Pooled it
- The Abnormal Alternations of Brain Imaging in Patients with Chronic Obstructive Pulmonary Disease: A Systematic Review.Journal of Alzheimer's disease reports · 2023Pooled it
- Risk of dementia or cognitive impairment in COPD patients: A meta-analysis of cohort studies.Frontiers in aging neuroscience · 2022Pooled it
- Bronchitis, COPD, and pneumonia after viral endemic of patients with leprosy on Sorok Island in South Korea.Naunyn-Schmiedeberg's archives of pharmacology · 2023Trial
- Trial
- Association of soluble tumor necrosis factor receptor 1 with tau pathology, brain atrophy, and cognitive decline: a longitudinal study.BMC medicine · 2026Article
- Global Trends of Cognition-Targeted Interventions in Chronic Lung Disease: A Bibliometric and Visualized Analysis.International journal of chronic obstructive pulmonary disease · 2026Review
- Does Cognitive Function Influence the Benefits of Multicomponent Team Interventions?Journal of the American Medical Directors Association · 2026Article
- Cigarette smoke-induced lung-brain barrier dysfunction drives neurocognitive impairment via inflammatory spill-over.Journal of neuroinflammation · 2025Article
- Cognitive decline before and after incident chronic respiratory disease.GeroScience · 2025Article
- Using machine learning models to predict the risk of mild cognitive impairment for COPD patients: A multi-cohort study.Comprehensive psychoneuroendocrinology · 2025Article
- Acupuncture Modulation of the Lung-Brain Axis in Alzheimer's Disease: Mechanisms and Therapeutic Perspectives.Brain sciences · 2025Review
- Subjective Cognitive Decline in COPD - A Cross-Sectional Analysis of the Behavioral Risk Factor Surveillance System.Journal of general internal medicine · 2025Article
- Association of pulmonary function with the risk of incident Alzheimer's disease: a prospective cohort and Mendelian randomization study.Aging clinical and experimental research · 2025Article
- Mesenchymal stem cell-derived exosomes-a promising therapeutic approach to improve neurocognitive disorders in chronic obstructive pulmonary disease.Stem cell research & therapy · 2025Review
- Presence of chronic morbidities alters skeletal muscle health and amino acid kinetics in mild cognitive impairment.Journal of Alzheimer's disease : JAD · 2025Article
- Asthma and COPD Beyond the Airways: Exploring Neurocognitive Links Through NF-κB Subunits c-Rel and p65.International journal of molecular sciences · 2025Article
- HO-1-Enriched Lung-Derived Exosomes Mediate Cognitive Impairment in a Mice Model of COPD Exacerbation.Canadian respiratory journal · 2025Article
- The association between preserved ratio impaired spirometry (PRISm) and cognitive function among American older adults: the mediating role of systolic blood pressure.BMC geriatrics · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
importancePrevious studies suggest cross-sectional associations between a diagnosis of chronic obstructive pulmonary disease (COPD) and mild cognitive impairment (MCI). However, few studies have assessed whether COPD, a potentially modifiable factor, is associated with an increased risk for MCI and whether the relation is specific to the type of MCI.
objectiveTo investigate whether a diagnosis of COPD and duration of COPD are associated with an increased risk for incident MCI and MCI subtypes (amnestic MCI [A-MCI] and nonamnestic MCI [NA-MCI]). DESIGN, SETTING, AND
participantsA prospective population-based cohort from the Mayo Clinic Study on Aging. We included 1425 cognitively normal individuals aged 70 to 89 years who were randomly selected from Olmsted County, Minnesota, on October 1, 2004, using the medical records linkage system. At baseline and every 15 months thereafter, participants underwent assessment with a nurse interview, neurologic examination, and neuropsychological testing. A diagnosis of COPD was confirmed via medical record review. A baseline diagnosis of COPD and duration of COPD were examined as risk factors for MCI and MCI subtypes using Cox proportional hazards models and adjusting for demographic variables and medical comorbidities, with age as the time scale. EXPOSURE: A baseline diagnosis of COPD and duration of COPD. MAIN OUTCOMES AND MEASURES: Incident MCI, A-MCI, and NA-MCI.
resultsOf the 1425 participants with normal cognition at baseline, 370 developed incident MCI. The median duration of follow-up was 5.1 years (interquartile range, 3.8-5.4 years). A diagnosis of COPD significantly increased the risk for NA-MCI by 83% (hazard ratio, 1.83 [95% CI, 1.04-3.23]), but not of any MCI or A-MCI in multivariate analyses. We found a dose-response relationship such that individuals with COPD duration of longer than 5 years at baseline had the greatest risk for any MCI (hazard ratio, 1.58 [95% CI, 1.04-2.40]) and NA-MCI (2.58 [1.32-5.06]). CONCLUSIONS AND RELEVANCE: A diagnosis of COPD is associated with an increased risk for MCI, particularly NA-MCI. We have found a dose-response relationship between COPD duration and risk for MCI. These findings highlight the importance of COPD as a risk factor for MCI and may provide a substrate for early intervention to prevent or delay the onset and progression of MCI, particularly NA-MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.